Balance Sheet Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 16/04/2026 BST			5-day change	1st Jan Change
13.55 ^HKD	+0.07%		+3.12%	+4.15%

03-31	Abbisko Cayman says irpagratinib granted orphan drug designation by EMA for hepatocellular carcinoma	RE
03-31	Abbisko Therapeutics Co., Ltd. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application for ABSK061	CI

93437.RIo6Ynr74-lnWx_6KejghnJRhwemLLBQ6hpM7VSdIXE.FslzDwi0hqNVOFy4XKea3F809XfFG_s6nXkJ2mTREyQFwgkLAJKusyArSg

Published financial data: ABBISKO CAYMAN LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	-	22.68M	-	19.06M	504M
Other Revenues, Total	7.3M	-	-	-	-
Total Revenues	7.3M	22.68M	-	19.06M	504M
Gross Profit	7.3M	22.68M	-	19.06M	504M
Selling General & Admin Expenses, Total	21.17M	125M	118M	96.4M	74.21M
R&D Expenses	133M	226M	379M	434M	451M
Other Operating Expenses, Total	154M	351M	497M	530M	526M
Operating Income	-147M	-328M	-497M	-511M	-21.59M
Interest Expense, Total	-338K	-959K	-2.68M	-2.17M	-1.61M
Interest And Investment Income	11.44M	16.94M	-	65.49M	89.1M
Net Interest Expenses	11.1M	15.98M	-2.68M	63.32M	87.49M
Currency Exchange Gains (Loss)	-	6.67M	-41.3M	-5.6M	1.8M
Other Non Operating Income (Expenses)	-571M	14M	45.56M	21.07M	10.34M
EBT, Excl. Unusual Items	-707M	-292M	-496M	-432M	78.03M
Gain (Loss) On Sale Of Investments	-	5.9M	-	706K	-
Other Unusual Items	-	-1.52B	-	-	-
EBT, Incl. Unusual Items	-707M	-1.81B	-496M	-432M	78.03M
Income Tax Expense	-	-	-	-	49.73M
Earnings From Continuing Operations	-707M	-1.81B	-496M	-432M	28.3M
Net Income to Company	-707M	-1.81B	-496M	-432M	28.3M
Net Income - (IS)	-707M	-1.81B	-496M	-432M	28.3M
Net Income to Common Incl Extra Items	-707M	-1.81B	-496M	-432M	28.3M
Net Income to Common Excl. Extra Items	-707M	-1.81B	-496M	-432M	28.3M
Per Share Items
Net EPS - Basic	-7.12	-7.71	-0.8	-0.67	0.04
Basic EPS - Continuing Operations	-7.12	-7.71	-0.8	-0.67	0.04
Basic Weighted Average Shares Outstanding	99.19M	235M	621M	647M	634M
Net EPS - Diluted	-7.12	-7.71	-0.8	-0.67	0.04
Diluted EPS - Continuing Operations	-7.12	-7.71	-0.8	-0.67	0.04
Diluted Weighted Average Shares Outstanding	99.19M	235M	621M	647M	650M
Normalized Basic EPS	-4.45	-0.78	-0.5	-0.42	0.08
Normalized Diluted EPS	-4.45	-0.78	-0.5	-0.42	0.08
Supplemental Items
EBITDA	-143M	-323M	-493M	-505M	-10.79M
EBITA	-146M	-328M	-497M	-511M	-21.59M
EBIT	-147M	-328M	-497M	-511M	-21.59M
EBITDAR	-	-	-491M	-504M	-10.02M
Effective Tax Rate - (Ratio)	-	-	-	-	63.73
Current Foreign Taxes	-	-	-	-	49.73M
Total Current Taxes	-	-	-	-	49.73M
Normalized Net Income	-442M	-182M	-310M	-270M	48.77M
Interest on Long-Term Debt	338K	959K	2.68M	2.17M	1.61M
Supplemental Operating Expense Items
General and Administrative Expenses	21.17M	125M	118M	96.4M	74.21M
Research And Development Expense From Footnotes	133M	226M	379M	434M	451M
Net Rental Expense, Total	-	-	1.35M	725K	770K
Imputed Operating Lease Interest Expense	-	-	584K	310K	330K
Imputed Operating Lease Depreciation	-	-	767K	415K	440K
Stock-Based Comp., R&D Exp. (Total)	3.48M	49.81M	65.11M	27.81M	13.77M
Stock-Based Comp., G&A Exp. (Total)	1.1M	40.12M	45.01M	19.59M	6.97M
Stock-Based Comp., Other (Total)	-	429K	-	-	-
Total Stock-Based Compensation	4.57M	90.36M	110M	47.4M	20.74M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	618M	2.55B	2.26B	1.97B	290M
Short Term Investments	18.89M	26.48M	26.05M	38.32M	1.72B
Trading Asset Securities, Total	-	-	93.8M	918K	233K
Total Cash And Short Term Investments	637M	2.57B	2.38B	2.01B	2.01B
Other Receivables	66K	-	7.74M	-	-
Notes Receivable	-	-	10.06M	9.38M	3.7M
Total Receivables	66K	-	17.8M	9.38M	3.7M
Other Current Assets, Total	13.08M	9.39M	11.25M	21.29M	9.05M
Total Current Assets	650M	2.58B	2.41B	2.04B	2.02B
Gross Property Plant And Equipment	24.54M	83.24M	95.82M	98.16M	88.16M
Accumulated Depreciation	-9.77M	-13.95M	-18.52M	-28.82M	-35.34M
Net Property Plant And Equipment	14.78M	69.29M	77.3M	69.35M	52.82M
Other Intangibles, Total	434K	3.05M	4.5M	4.63M	4.83M
Other Long-Term Assets, Total	960K	805K	27K	-	28.97M
Total Assets	666M	2.65B	2.49B	2.12B	2.11B
Liabilities
Accrued Expenses, Total	8.29M	22.3M	23.2M	81.65M	93.74M
Current Portion of Leases	4.31M	8.86M	9.97M	10.61M	11.02M
Current Income Taxes Payable	403K	1.3M	24.05M	2.11M	16.14M
Other Current Liabilities	18.75M	41.08M	50.34M	14.79M	14.55M
Total Current Liabilities	31.75M	73.54M	108M	109M	135M
Long-Term Debt	1.72B	-	-	-	-
Long-Term Leases	-	44.94M	35.61M	25.11M	13.27M
Other Non Current Liabilities	19.58M	-	-	-	-
Total Liabilities	1.77B	118M	143M	134M	149M
Common Stock, Total	6K	46K	46K	46K	44K
Additional Paid In Capital	-	5.37B	5.5B	5.49B	5.49B
Retained Earnings	-1.17B	-2.98B	-3.48B	-3.91B	-3.88B
Treasury Stock	-	-5K	-3K	-4K	-3K
Comprehensive Income and Other	64.89M	146M	323M	395M	347M
Total Common Equity	-1.1B	2.54B	2.35B	1.98B	1.96B
Total Equity	-1.1B	2.54B	2.35B	1.98B	1.96B
Total Liabilities And Equity	666M	2.65B	2.49B	2.12B	2.11B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	99.19M	695M	647M	647M	629M
ECS Total Common Shares Outstanding	99.19M	695M	647M	647M	629M
Book Value / Share	-11.14	3.65	3.62	3.06	3.11
Tangible Book Value	-1.11B	2.53B	2.34B	1.98B	1.95B
Tangible Book Value Per Share	-11.14	3.64	3.62	3.05	3.11
Total Debt	1.72B	53.8M	45.58M	35.72M	24.29M
Net Debt	1.09B	-2.52B	-2.33B	-1.98B	-1.98B
Debt Equivalent Oper. Leases	-	-	10.81M	5.8M	6.16M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	18.31M	25.41M	33.27M	45.33M	47.61M
Full Time Employees	-	160	250	258	281

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-707M	-1.81B	-496M	-432M	28.3M
Depreciation & Amortization - CF	9.35M	11.18M	14.12M	15.76M	20.44M
Amortization of Goodwill and Intangible Assets - (CF)	138K	704K	-	-	-
Depreciation & Amortization, Total	9.49M	11.89M	14.12M	15.76M	20.44M
Amortization of Deferred Charges, Total - (CF)	-	29.2M	1.67M	2.66M	3.13M
(Gain) Loss From Sale Of Asset	-	-	-	59K	28K
(Gain) Loss on Sale of Investments - (CF)	-166K	-	219K	-1.14M	692K
Stock-Based Compensation (CF)	4.57M	90.36M	110M	47.4M	20.74M
Other Operating Activities, Total	564M	1.5B	8.67M	-57.28M	-93.85M
Change In Accounts Payable	15.09M	28.31M	18.82M	1.72M	2.5M
Change in Other Net Operating Assets	-4.12M	-21.18M	-1.92M	-22.32M	5.1M
Cash from Operations	-118M	-170M	-344M	-445M	-12.92M
Capital Expenditure	-3.46M	-9.01M	-19.62M	-9.6M	-4.07M
Sale (Purchase) of Intangible assets	-572K	-3.32M	-3.13M	-2.65M	-3.33M
Investment in Marketable and Equity Securities, Total	166K	-1.48B	-214M	345M	-248M
Other Investing Activities, Total	-7.38M	28.81M	20.32M	46.14M	59.36M
Cash from Investing	-11.25M	-1.46B	-217M	379M	-197M
Long-Term Debt Repaid, Total	-5.08M	-7.41M	-8.64M	-9.44M	-9.46M
Total Debt Repaid	-5.08M	-7.41M	-8.64M	-9.44M	-9.46M
Issuance of Common Stock	-	1.45B	3.74M	8.42M	6.53M
Repurchase of Common Stock	-	-	-4.06M	-12.91M	-76.32M
Issuance of Preferred Stock	511M	777M	-	-	-
Other Financing Activities, Total	-422K	-119M	-11.86M	-2.17M	-1.61M
Cash from Financing	506M	2.1B	-20.81M	-16.1M	-80.86M
Foreign Exchange Rate Adjustments	-44.95M	-26.31M	159M	18.55M	1.74M
Net Change in Cash	332M	446M	-422M	-63.76M	-289M
Supplemental Items
Cash Interest Paid	-	959K	2.68M	2.17M	1.61M
Cash Income Tax Paid (Refund)	-	-	-	-	78.69M
Levered Free Cash Flow	-76.69M	-45.64M	-196M	-268M	73.63M
Unlevered Free Cash Flow	-76.48M	-45.04M	-194M	-267M	74.64M
Change In Net Working Capital	-5.07M	-40.98M	-13.25M	654K	-51.22M
Net Debt Issued / Repaid	-5.08M	-7.41M	-8.64M	-9.44M	-9.46M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-18.57	-12.36	-12.08	-13.87	-0.64
Return on Total Capital	-19.76	-12.79	-12.48	-14.49	-0.67
Return On Equity %	90.36	-252.96	-20.3	-19.95	1.44
Return on Common Equity	90.36	-252.96	-20.3	-19.95	1.44
Margin Analysis
Gross Profit Margin %	100	100	-	100	100
SG&A Margin	289.89	550.11	-	505.78	14.72
EBITDA Margin %	-1.96K	-1.43K	-	-2.65K	-2.14
EBITA Margin %	-2K	-1.44K	-	-2.68K	-4.28
EBIT Margin %	-2.01K	-1.45K	-	-2.68K	-4.28
Income From Continuing Operations Margin %	-9.68K	-7.98K	-	-2.26K	5.62
Net Income Margin %	-9.68K	-7.98K	-	-2.26K	5.62
Net Avail. For Common Margin %	-9.68K	-7.98K	-	-2.26K	5.62
Normalized Net Income Margin	-6.05K	-803.43	-	-1.42K	9.68
Levered Free Cash Flow Margin	-1.05K	-201.23	-	-1.41K	14.61
Unlevered Free Cash Flow Margin	-1.05K	-198.59	-	-1.4K	14.81
Asset Turnover
Asset Turnover	0.01	0.01	-	0.01	0.24
Fixed Assets Turnover	0.42	0.54	-	0.26	8.25
Short Term Liquidity
Current Ratio	20.47	35.1	22.39	18.7	14.92
Quick Ratio	20.05	34.98	22.19	18.42	14.82
Operating Cash Flow to Current Liabilities	-3.7	-2.31	-3.2	-4.07	-0.1
Long Term Solvency
Total Debt/Equity	-156.01	2.12	1.94	1.8	1.24
Total Debt / Total Capital	278.53	2.08	1.91	1.77	1.22
LT Debt/Equity	-155.62	1.77	1.52	1.27	0.68
Long-Term Debt / Total Capital	277.83	1.74	1.49	1.25	0.67
Total Liabilities / Total Assets	265.92	4.46	5.75	6.35	7.06
EBIT / Interest Expense	-433.52	-342.25	-185.17	-235.52	-13.43
EBITDA / Interest Expense	-405.44	-329.86	-179.91	-228.25	-0.72
(EBITDA - Capex) / Interest Expense	-415.68	-339.26	-187.22	-232.68	-3.25
Total Debt / EBITDA	-12.58	-0.17	-0.09	-0.07	-21.03
Net Debt / EBITDA	-7.93	7.96	4.83	3.99	1.72K
Total Debt / (EBITDA - Capex)	-12.27	-0.17	-0.09	-0.07	-4.65
Net Debt / (EBITDA - Capex)	-7.74	7.74	4.64	3.91	379.67
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	90.3	-	-	-	2.54K
Gross Profit, 1 Yr. Growth %	90.3	-	-	-	2.54K
EBITDA, 1 Yr. Growth %	48.24	115.25	52.02	2.46	-97.86
EBITA, 1 Yr. Growth %	47.11	113.1	51.48	2.79	-95.77
EBIT, 1 Yr. Growth %	47.25	113.36	51.48	2.79	-95.77
Earnings From Cont. Operations, 1 Yr. Growth %	427.69	156.14	-72.62	-12.92	-106.56
Net Income, 1 Yr. Growth %	427.69	156.14	-72.62	-12.92	-106.56
Normalized Net Income, 1 Yr. Growth %	427.69	112.49	73.49	-12.78	-118.05
Diluted EPS Before Extra, 1 Yr. Growth %	-	8.17	-89.64	-16.49	-105.97
Net Property, Plant and Equip., 1 Yr. Growth %	-26.33	368.99	11.55	-10.29	-23.83
Total Assets, 1 Yr. Growth %	107.96	298.6	-6.22	-15.03	-0.39
Tangible Book Value, 1 Yr. Growth %	140.82	-329.14	-7.55	-15.6	-1.16
Common Equity, 1 Yr. Growth %	140.72	-329.51	-7.48	-15.57	-1.15
Cash From Operations, 1 Yr. Growth %	41.95	38.17	102.6	29.32	-97.09
Capital Expenditures, 1 Yr. Growth %	0.79	160.37	117.64	-51.05	-57.63
Levered Free Cash Flow, 1 Yr. Growth %	-	-43.83	329.41	36.67	-126.75
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-44.42	331.4	37.15	-127.25
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	143.13	-	-8.33	-
Gross Profit, 2 Yr. CAGR %	-	143.13	-	-8.33	-
EBITDA, 2 Yr. CAGR %	-	83.14	81.09	24.81	-85.2
EBITA, 2 Yr. CAGR %	-	81.42	79.86	24.78	-79.16
EBIT, 2 Yr. CAGR %	-	81.61	79.78	24.78	-79.16
Earnings From Cont. Operations, 2 Yr. CAGR %	-	267.64	-16.25	-51.17	-76.1
Net Income, 2 Yr. CAGR %	-	267.64	-16.25	-51.17	-76.1
Normalized Net Income, 2 Yr. CAGR %	-	47.56	90.05	23.01	-60.32
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-66.52	-70.58	-77.62
Net Property, Plant and Equip., 2 Yr. CAGR %	-	85.88	128.73	0.04	-17.34
Total Assets, 2 Yr. CAGR %	-	187.91	93.34	-10.73	-8
Tangible Book Value, 2 Yr. CAGR %	-	134.91	45.55	-11.67	-8.67
Common Equity, 2 Yr. CAGR %	-	135.05	45.72	-11.62	-8.64
Cash From Operations, 2 Yr. CAGR %	-	43.16	67.31	61.87	-80.61
Capital Expenditures, 2 Yr. CAGR %	-	61.99	138.05	3.22	-54.46
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	55.31	142.26	-38.71
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	54.84	143.24	-38.02
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-	-	181.13
Gross Profit, 3 Yr. CAGR %	-	-	-	-	181.13
EBITDA, 3 Yr. CAGR %	-	-	72.24	49.78	-67.83
EBITA, 3 Yr. CAGR %	-	-	70.96	49.26	-59.63
EBIT, 3 Yr. CAGR %	-	-	70.96	49.22	-59.63
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	54.68	-15.16	-74.99
Net Income, 3 Yr. CAGR %	-	-	54.68	-15.16	-74.99
Normalized Net Income, 3 Yr. CAGR %	-	-	54.68	46.6	-35.12
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-54.6	-82.69
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	56.79	67.43	-8.65
Total Assets, 3 Yr. CAGR %	-	-	98.1	47	-7.41
Tangible Book Value, 3 Yr. CAGR %	-	-	72.15	21.37	-8.3
Common Equity, 3 Yr. CAGR %	-	-	72.26	21.48	-8.26
Cash From Operations, 3 Yr. CAGR %	-	-	60.73	53.55	-57.62
Capital Expenditures, 3 Yr. CAGR %	-	-	78.75	40.51	-23.29
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	48.83	17.28
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	48.71	18.33
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	-	165.27
Gross Profit, 5 Yr. CAGR %	-	-	-	-	165.27
EBITDA, 5 Yr. CAGR %	-	-	-	-	-35.47
EBITA, 5 Yr. CAGR %	-	-	-	-	-26.33
EBIT, 5 Yr. CAGR %	-	-	-	-	-26.33
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	-26.72
Net Income, 5 Yr. CAGR %	-	-	-	-	-26.72
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	-10.24
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	21.37
Total Assets, 5 Yr. CAGR %	-	-	-	-	45.76
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	33.6
Common Equity, 5 Yr. CAGR %	-	-	-	-	33.66
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	-31.03
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	3.45